Journal Article

Meningococcal B Immunisation in Adults and Potential Broader Immunisation Strategies: A Narrative Review

Banzhoff, Angelika, Khalaf, Mansour, Abbing-Karahagopian, Victoria, Badur, Selim, Ozturk, Serdar, Kassianos, George, Barasheed, Osamah

2023

Overview

Recombinant vaccines against invasive meningococcal disease due to Neisseria meningitidis serogroup B (MenB) have shown substantial impact in reducing MenB disease in targeted populations. 4CMenB targets four key N. meningitidis protein antigens; human factor H binding protein (fHbp), Neisserial heparin binding antigen (NHBA), Neisseria adhesin A (NadA) and the porin A protein (PorA P1.4), with one or more of these expressed by most pathogenic MenB strains, while MenB-FHbp targets two distinct fHbp variants. While many countries recommend MenB immunisation in adults considered at high risk due to underlying medical conditions or immunosuppression, there are no recommendations for routine use in the general adult population. We reviewed the burden of MenB in adults, where, while incidence rates remain low (and far lower than in young children < 5 years of age at greatest risk), a substantial proportion of MenB cases (20% or more) is now observed in the adult population; evident in Europe, Australia, and in the United States. We also reviewed immunogenicity data in adults from clinical studies conducted during MenB vaccine development and subsequent post-licensure studies. A 2-dose schedule of 4CMenB generates hSBA titres ≥ 1:4 towards all four key vaccine target antigens in up to 98–100% of subjects. For MenB-FHbp, a ≥ fourfold rise in hSBA titres against the four primary representative test strains was observed in 70–95% of recipients following a 3-dose schedule. While this suggests potential benefits for MenB immunisation if used in adult populations, data are limited (especially for adults > 50 years) and key aspects relating to duration of protection remain unclear. Although a broader adult MenB immunisation policy could provide greater protection of the adult population, additional data are required to support policy decision-making. Graphical Abstract

• Publisher: Springer Healthcare,Springer,Springer Nature B.V,Adis, Springer Healthcare
• Subject: 4CMenB / Adults / Antigens / Decision-making / Human factors / Immunization / Immunogenicity / Infectious Diseases / Internal Medicine / Medicine / Medicine & Public Health / MenB / MenB-FHbp / Meningitis / Meningococcal disease / Neisseria meningitidis serogroup B / Protein binding / Proteins / Review / Vaccines